Journal
EXPERT OPINION ON EMERGING DRUGS
Volume 12, Issue 4, Pages 541-554Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728214.12.4.541
Keywords
anxiety disorders; anxiolytics; benzodiazepines; corticotropin-releasing factor; D-cycloserine; memantine; neurokinins; pregabalin; propranolol; selective serotonin re-uptake inhibitors
Categories
Ask authors/readers for more resources
Anxiety disorders are the most common of the psychiatric disorders and are also associated with significant economic costs and impaired work productivity. The first-line pharmacotherapy of pharmatherapy for a number of anxiety disorders comprises selective serotonin re-uptake inhibitors (SSRIs) and serotonin and noradrenaline re-uptake inhibitors (SNRIs). Benzodiazepines are still widely used for the treatment of several anxiety disorders. Although these agents are effective, many patients are treatment-refractory and more effective, better tolerated medications are required. This paper discusses the understandings of mechanisms involved in the anxiety disorders and reviews emerging medications. Mechanisms underlying the use of D-cycloserine, second generation antipsychotics and beta-blockers are particularly exciting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available